MAPT and Alzheimer disease: For instance, utilizing polygenic risk scores, along with the APOE4 genotype and astrocytic activation markers, such as glial fibrillary acidic protein (GFAP), and AD biomarkers like phosphorylated tau at threonine 181 (p-tau181), can lead to an increased precision in risk estimates among APOE4 carriers [101].